Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSI Puts Eye Disease Franchise On The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Ongoing Macugen trials look promising, but OSI chooses to put its R&D funds into diabetes and oncology businesses, CEO tells analysts.

You may also be interested in...



OSI, Aveo Development Deal To Focus On EMT Mechanisms In Cancer

Collaboration aims to position OSI as a leader in the emerging area of epithelial-mesenchymal transition, CEO Goddard says.

OSI, Aveo Development Deal To Focus On EMT Mechanisms In Cancer

Collaboration aims to position OSI as a leader in the emerging area of epithelial-mesenchymal transition, CEO Goddard says.

OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Goddard talks about OSI’s pipeline, dealing with competition from Pfizer and Genentech, and how he plans to “demonstrate a full year of profitability” in 2007.

Related Content

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel